Li Jing, Liu Wenxiu, Peng Fu, Cao Xiaoyu, Xie Xiaofang, Peng Cheng
Key Laboratory of Southwestern Chinese Medicine Resources, Key Laboratory of standardization of Chinese herbal medicine of MOE, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Department of Pharmacology, Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China.
Front Genet. 2023 Mar 10;14:1132884. doi: 10.3389/fgene.2023.1132884. eCollection 2023.
Cardio-cerebrovascular disease, related to high mortality and morbidity worldwide, is a type of cardiovascular or cerebrovascular dysfunction involved in various processes. Therefore, it is imperative to conduct additional research into the pathogenesis and new therapeutic targets of cardiovascular and cerebrovascular disorders. Long non-coding RNAs (lncRNAs) have multiple functions and are involved in nearly all cellular biological processes, including translation, transcription, signal transduction, and cell cycle control. LncR-Meg3 is one of them and is becoming increasingly popular. By binding proteins or directly or competitively binding miRNAs, LncR-Meg3 is involved in apoptosis, inflammation, oxidative stress, endoplasmic reticulum stress, epithelial-mesenchymal transition, and other processes. Recent research has shown that LncR-Meg3 is associated with acute myocardial infarction and can be used to diagnose this condition. This article examines the current state of knowledge regarding the expression and regulatory function of LncR-Meg3 in relation to cardiovascular and cerebrovascular diseases. The abnormal expression of LncR-Meg3 can influence neuronal cell death, inflammation, apoptosis, smooth muscle cell proliferation, etc., thereby aggravating or promoting the disease. In addition, we review the bioactive components that target lncR-Meg3 and propose some potential delivery vectors. A comprehensive and in-depth analysis of LncR-Meg3's role in cardiovascular disease suggests that targeting LncR-Meg3 may be an alternative therapy in the near future, providing new options for slowing the progression of cardiovascular disease.
心脑血管疾病在全球范围内具有较高的死亡率和发病率,是一种涉及多种过程的心血管或脑血管功能障碍。因此,有必要对心脑血管疾病的发病机制和新的治疗靶点进行更多研究。长链非编码RNA(lncRNAs)具有多种功能,几乎参与所有细胞生物学过程,包括翻译、转录、信号转导和细胞周期调控。LncR-Meg3就是其中之一,并且越来越受到关注。通过结合蛋白质或直接或竞争性结合微小RNA(miRNAs),LncR-Meg3参与细胞凋亡、炎症、氧化应激、内质网应激、上皮-间质转化等过程。最近的研究表明,LncR-Meg3与急性心肌梗死有关,可用于诊断该疾病。本文探讨了LncR-Meg3在心血管疾病中表达和调控功能的研究现状。LncR-Meg3的异常表达可影响神经元细胞死亡、炎症、凋亡、平滑肌细胞增殖等,从而加重或促进疾病发展。此外,我们综述了靶向lncR-Meg3的生物活性成分,并提出了一些潜在的递送载体。对LncR-Meg3在心血管疾病中作用的全面深入分析表明,靶向LncR-Meg3可能在不久的将来成为一种替代疗法,为减缓心血管疾病的进展提供新的选择。